Latest Ankylosing Spondylitis news
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
posted July 9th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Bimzelx for Three New Indications
posted September 26th
by modernClinician Editorial Team
by modernClinician Editorial Team
Secukinumab Cuts Symptoms of Ankylosing Spondylitis
posted December 23rd
by modernClinician Editorial Team
by modernClinician Editorial Team
For patients with active ankylosing spondylitis, secukinumab is associated with reductions in symptoms at week 16, according to a study published in the Dec. 24 issue of the New England Journal of Medicine.
Editor's Recommendations
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV 
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines 
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine Related Articles
Achieving PSA <0.2 ng/mL Improves Survival in Metastatic Castration-Sensitive Prostate Cancer 
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment 
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma Monthly Specialist Briefings
Stay Connected
